Stay updated on 89Zr-Pembrolizumab in NSCLC Clinical Trial

Sign up to get notified when there's something new on the 89Zr-Pembrolizumab in NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the 89Zr-Pembrolizumab in NSCLC Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    The page's revision tag was updated to v3.5.4, indicating a small documentation or backend update. The visible study information and layout remain unchanged.
    Difference
    0.1%
    Check dated 2026-05-15T16:30:45.000Z thumbnail image
  2. Check
    12 days ago
    No Change Detected
  3. Check
    19 days ago
    No Change Detected
  4. Check
    27 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov page revision label updates from **v3.5.2** to **v3.5.3**, indicating a site/version release with no change to the study’s informational content.
    Difference
    0.1%
    Check dated 2026-04-24T05:50:06.000Z thumbnail image
  5. Check
    34 days ago
    Change Detected
    Summary
    Revision updated from v3.5.0 to v3.5.2.
    Difference
    0.1%
    Check dated 2026-04-17T02:13:13.000Z thumbnail image
  6. Check
    63 days ago
    Change Detected
    Summary
    Added a new version label 'Revision: v3.5.0' and removed 'Revision: v3.4.3' from the site metadata.
    Difference
    0.1%
    Check dated 2026-03-19T05:06:53.000Z thumbnail image
  7. Check
    70 days ago
    Change Detected
    Summary
    Revision updated from v3.4.2 to v3.4.3. This appears to be a minor site version update with no visible changes to core content or functionality.
    Difference
    0.1%
    Check dated 2026-03-12T02:25:26.000Z thumbnail image
  8. Check
    98 days ago
    Change Detected
    Summary
    Added Revision: v3.4.2 and removed the funding-lapse notice along with Revision: v3.4.1.
    Difference
    0.5%
    Check dated 2026-02-11T11:32:22.000Z thumbnail image

Stay in the know with updates to 89Zr-Pembrolizumab in NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the 89Zr-Pembrolizumab in NSCLC Clinical Trial page.